Rpt-sys

Emotional Rebalance


Vitality Works, Inc.
Human Otc Drug
NDC 64616-104
Rpt-sys also known as Emotional Rebalance is a human otc drug labeled by 'Vitality Works, Inc.'. National Drug Code (NDC) number for Rpt-sys is 64616-104. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Rpt-sys drug includes Apocynum Cannabinum Root - 10 [hp_X]/mL Asafetida - 6 [hp_X]/mL Egg Phospholipids - 20 [hp_X]/mL Eucalyptus Globulus Leaf - 7 [hp_X]/mL Gentiana Lutea Root - 7 [hp_X]/mL Lathyrus Sativas Seed - 20 [hp_X]/mL Lycopodium Clavatum Spore - 7 [hp_X]/mL Nutmeg - 7 [hp_X]/mL Oxalic Acid Dihydrate - 10 [hp_X]/mL Phosphoric Acid - 8 [hp_X]/mL and more. The currest status of Rpt-sys drug is Active.

Drug Information:

Drug NDC: 64616-104
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Rpt-sys
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Emotional Rebalance
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Vitality Works, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:APOCYNUM CANNABINUM ROOT - 10 [hp_X]/mL
ASAFETIDA - 6 [hp_X]/mL
EGG PHOSPHOLIPIDS - 20 [hp_X]/mL
EUCALYPTUS GLOBULUS LEAF - 7 [hp_X]/mL
GENTIANA LUTEA ROOT - 7 [hp_X]/mL
LATHYRUS SATIVAS SEED - 20 [hp_X]/mL
LYCOPODIUM CLAVATUM SPORE - 7 [hp_X]/mL
NUTMEG - 7 [hp_X]/mL
OXALIC ACID DIHYDRATE - 10 [hp_X]/mL
PHOSPHORIC ACID - 8 [hp_X]/mL
PLATINUM - 10 [hp_X]/mL
SILICON DIOXIDE - 10 [hp_X]/mL
SODIUM BORATE - 7 [hp_X]/mL
STRYCHNOS IGNATII SEED - 10 [hp_X]/mL
SUS SCROFA PITUITARY GLAND - 6 [hp_C]/mL
THYROID, UNSPECIFIED - 6 [hp_C]/mL
TOXICODENDRON PUBESCENS LEAF - 10 [hp_X]/mL
TRILLIUM ERECTUM ROOT - 3 [hp_X]/mL
WOOD CREOSOTE - 8 [hp_X]/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 08 Apr, 2013
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 08 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Vitality Works, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000185371
N0000185375
N0000175629
N0000184306
M0000728
M0016962
M0006342
M0008672
M0516536
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:2F92409L9Z
W9FZA51AS1
1Z74184RGV
S546YLW6E6
S72O3284MS
8VP54WOT4I
C88X29Y479
AEE24M3MQ9
0K2L2IJ59O
E4GA8884NN
49DFR088MY
ETJ7Z6XBU4
91MBZ8H3QO
1NM3M2487K
L0PFEMQ1DT
0B4FDL9I6P
6IO182RP7A
AHW6F0T2X0
3JYG22FD73
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Plant Proteins [CS]
Dietary Proteins [CS]
Food Additives [CS]
Seed Storage Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Dietary Proteins [CS]
Food Additives [CS]
Increased Histamine Release [PE]
Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Plant Proteins [CS]
Seed Storage Proteins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
64616-104-0259 mL in 1 BOTTLE, DROPPER (64616-104-02)08 Apr, 2013N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Rpt-sys focuses on the vibrational and electrical balances to the body.

Product Elements:

Rpt-sys emotional rebalance alcohol water apocynum cannabinum root apocynum cannabinum root asafetida asafetida sodium borate borate ion eucalyptus globulus leaf eucalyptus globulus leaf gentiana lutea root gentiana lutea root strychnos ignatii seed strychnos ignatii seed wood creosote wood creosote lathyrus sativas seed lathyrus sativas seed egg phospholipids egg phospholipids lycopodium clavatum spore lycopodium clavatum spore nutmeg nutmeg oxalic acid dihydrate oxalic acid phosphoric acid phosphoric acid sus scrofa pituitary gland sus scrofa pituitary gland platinum platinum toxicodendron pubescens leaf toxicodendron pubescens leaf silicon dioxide silicon dioxide thyroid, unspecified thyroid, unspecified trillium erectum root trillium erectum root

Indications and Usage:

Rpt-sys for the temporary relief of anxiety, confusion, memory loss, and depression.

Warnings:

Rpt-sys use only under the direction of a health care professional. do not use if tamper evident seal is broken or missing.

Dosage and Administration:

Rpt-sys orally 25 drops, 2 times per day or an indicated by a physician. children 12 and under use one half the adult dosage.

Package Label Principal Display Panel:

Rpt-sys label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.